Physician profile
Mechelle T Perry
NPI 1225150667
$11,831.13
in general payments reported to CMS, 2019-2025
37 companies · $2,694 in 2025
The $2,694 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,864 · 2022: $1,989 · 2023: $1,925 · 2024: $2,359 · 2025: $2,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,977.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,846.66 | 2021-2025 | |
| Novo Nordisk INC | $1,813.61 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $898.73 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $566.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $505.33 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $503.07 | 2021 | |
| Pfizer INC. | $406.09 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $365.48 | 2021-2024 | Spravato |
| Glaxosmithkline, LLC. | $324.13 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $323.65 | 2024-2025 | Auvelity, Symbravo |
| Vanda Pharmaceuticals INC. | $311.87 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $300.89 | 2021-2025 | Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $269.85 | 2022-2025 | Caplyta |
| Lundbeck LLC | $240.81 | 2022-2025 | Vyepti, Rexulti |
| Amarin Pharma, INC. | $210.07 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $180.29 | 2022 | |
| Idorsia Pharmaceuticals US INC | $179.14 | 2022-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $170.00 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $167.78 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.24 | 2021-2025 | Tradjenta, Synjardy, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.72 | 2021-2024 | Xifaxan, Trulance |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Neurocrine Biosciences, INC. | $120.03 | 2021 | |
| Merck Sharp & Dohme LLC | $106.96 | 2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $100.40 | 2022-2024 | |
| Dexcom, INC. | $97.01 | 2021-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $96.80 | 2021-2025 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $63.08 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $52.60 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $52.03 | 2021-2025 | Austedo Xr |
| Azurity Pharmaceuticals, INC. | $33.92 | 2023 | Edarbi |
| Eisai INC. | $29.31 | 2021-2022 | |
| Pulmonx Corporation | $26.21 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Abbott Laboratories | $23.90 | 2021 | |
| Exact Sciences Corporation | $19.91 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $16.26 | 2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mechelle Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.